­
­
­
­

Inventi Impact: Cancer Nursing

Articles

  • Inventi:hccn/25954/18
    Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after\nComprehensive Treatments Including Autologous Formalin-Fixed Tumor Vaccine
    01-Jan-1970 Research 2018 : July - September
    Fumito Kuranishi , Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno

    Introduction. No effective treatment has been developed for bone-metastatic breast cancer.We found 3 cases with clinical complete\nresponse (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively\nincluding autologous formalin-fixed tumor vaccine (AFTV). Patients and Methods. AFTV was prepared individually for each\npatient from their own formalin-fixed and paraffin-embedded breast cancer tissues. Results. Three patients maintained cCR status\nof the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive\ntreatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of\nbone metastasis were greater than those of historical control cohorts in Japan (1988ââ?¬â??2002) and in the nationwide population-based\ncohort study of Denmark (1999ââ?¬â??2007). Conclusion. Bone-metastatic breast cancer may be curable after comprehensive treatments\nincluding AFTV, although larger scale clinical trial is required.

    How to Cite this Article
    CC Compliant Citation: Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, et al., â??Rate of Clinical Complete Response for 1 Year or More in\nBone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine,â? International\nJournal of Breast Cancer, vol. 2018, Article ID 4879406, 11 pages, 2018. doi:10.1155/2018/4879406, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text